JP6962819B2 - 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法 - Google Patents

親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法 Download PDF

Info

Publication number
JP6962819B2
JP6962819B2 JP2017553132A JP2017553132A JP6962819B2 JP 6962819 B2 JP6962819 B2 JP 6962819B2 JP 2017553132 A JP2017553132 A JP 2017553132A JP 2017553132 A JP2017553132 A JP 2017553132A JP 6962819 B2 JP6962819 B2 JP 6962819B2
Authority
JP
Japan
Prior art keywords
less
unit
units
antibody
parent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553132A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512431A (ja
JP2018512431A5 (enExample
Inventor
ユルゲン ヘルマン ネット，
ケー． デーン ウィットラプ，
マキシミリアーノ バスケス，
Original Assignee
アディマブ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アディマブ， エルエルシー filed Critical アディマブ， エルエルシー
Publication of JP2018512431A publication Critical patent/JP2018512431A/ja
Publication of JP2018512431A5 publication Critical patent/JP2018512431A5/ja
Application granted granted Critical
Publication of JP6962819B2 publication Critical patent/JP6962819B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B01D15/168—Fluid composition conditioning, e.g. gradient pH gradient or chromatofocusing, i.e. separation according to the isoelectric point pI
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26—Cation exchangers for chromatographic processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
    • B01J41/20—Anion exchangers for chromatographic processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2017553132A 2015-04-10 2016-04-08 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法 Active JP6962819B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562146116P 2015-04-10 2015-04-10
US62/146,116 2015-04-10
US201562249180P 2015-10-30 2015-10-30
US62/249,180 2015-10-30
PCT/US2016/026620 WO2016164708A1 (en) 2015-04-10 2016-04-08 Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080220A Division JP7111767B2 (ja) 2015-04-10 2020-04-30 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法

Publications (3)

Publication Number Publication Date
JP2018512431A JP2018512431A (ja) 2018-05-17
JP2018512431A5 JP2018512431A5 (enExample) 2019-05-09
JP6962819B2 true JP6962819B2 (ja) 2021-11-05

Family

ID=57072068

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017553132A Active JP6962819B2 (ja) 2015-04-10 2016-04-08 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
JP2020080220A Active JP7111767B2 (ja) 2015-04-10 2020-04-30 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
JP2021085111A Pending JP2021119207A (ja) 2015-04-10 2021-05-20 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020080220A Active JP7111767B2 (ja) 2015-04-10 2020-04-30 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
JP2021085111A Pending JP2021119207A (ja) 2015-04-10 2021-05-20 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法

Country Status (6)

Country Link
US (2) US10787500B2 (enExample)
EP (1) EP3280444B1 (enExample)
JP (3) JP6962819B2 (enExample)
CN (1) CN108472360B (enExample)
AU (2) AU2016245887B2 (enExample)
WO (1) WO2016164708A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
DK3126384T3 (da) * 2014-04-01 2021-01-18 Adimab Llc Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN108472360B (zh) 2015-04-10 2023-01-17 阿迪马布有限责任公司 从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
ES3055961T3 (en) 2016-04-28 2026-02-17 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
CN109415444B (zh) 2016-07-29 2024-03-01 中外制药株式会社 显示增加的备选fviii辅因子功能活性的双特异性抗体
EP3509637B1 (en) 2016-09-06 2024-11-27 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
EP3603670A4 (en) 2017-03-31 2021-03-10 Public University Corporation Nara Medical University MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII
JP6496095B1 (ja) 2017-09-29 2019-04-03 中外製薬株式会社 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
TW202600611A (zh) * 2017-11-01 2026-01-01 日商中外製藥股份有限公司 生物活性降低之抗體變異體與同功型
US12152056B2 (en) * 2018-08-17 2024-11-26 Regeneron Pharmaceuticals, Inc. Method and chromatography system for determining amount and purity of a multimeric protein
AU2019343053B2 (en) * 2018-09-21 2026-04-30 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
US11022585B2 (en) 2019-06-09 2021-06-01 Dionex Corporation Methods and systems for optimizing buffer conditions with liquid chromatography
CN114539416B (zh) * 2020-11-26 2024-11-08 盛禾(中国)生物制药有限公司 一种双特异性抗体的层析纯化工艺

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US459004A (en) 1891-09-08 Box for steaming cops
US231A (en) 1837-06-10 Stove for heating irons for the use of tailors
US8188A (en) 1851-07-01 Htkstaht
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
EP0527809B1 (en) 1990-04-05 1995-08-16 CREA, Roberto Walk-through mutagenesis
US5492817A (en) 1993-11-09 1996-02-20 Promega Corporation Coupled transcription and translation in eukaryotic cell-free extract
US5665563A (en) 1991-10-11 1997-09-09 Promega Corporation Coupled transcription and translation in eukaryotic cell-free extract
DE69216385T2 (de) 1991-10-11 1997-06-12 Promega Corp Gekoppelte transkription und translation in zellfreien eukaryoten-extrakten
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US20030036092A1 (en) 1991-11-15 2003-02-20 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
US6165718A (en) 1996-01-10 2000-12-26 Novo Nordisk A/S Novo Alle Method for in vivo production of a mutant library in cells
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
DK0971946T3 (da) 1997-01-21 2006-10-30 Gen Hospital Corp Selektion af proteiner ved anvendelse af RNA-protein-fusioner
JP4093507B2 (ja) * 1997-03-10 2008-06-04 旭化成ファーマ株式会社 緩衝液組成
US6159688A (en) 1997-03-18 2000-12-12 Novo Nordisk A/S Methods of producing polynucleotide variants
JP4086325B2 (ja) 1997-04-23 2008-05-14 プリュックテュン，アンドレアス 標的分子と相互作用する（ポリ）ペプチドをコードする核酸分子の同定方法
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
PT1360288E (pt) 2000-12-18 2011-03-07 Dyax Corp Bibliotecas orientadas de pacotes genéticos
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2006020258A2 (en) 2004-07-17 2006-02-23 Imclone Systems Incorporated Novel tetravalent bispecific antibody
CA2603264C (en) 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
CN101460622A (zh) * 2006-03-31 2009-06-17 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
EP2009101B1 (en) * 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
US8580532B2 (en) 2006-12-21 2013-11-12 Sekisui Medical Co., Ltd. Method for stabilizing α-thrombin in thrombin-containing solution
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
JP2010538012A (ja) 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド Ｉｇｆ−１ｒの複数のエピトープに結合する組成物
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN101939776A (zh) 2008-03-06 2011-01-05 富士电机控股株式会社 有源矩阵型显示设备
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
CN102471377B (zh) * 2009-07-24 2015-04-22 霍夫曼-拉罗奇有限公司 优化抗体的生产
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
RU2016105962A (ru) 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
CA2796633C (en) * 2010-04-23 2020-10-27 Genentech, Inc. Production of heteromultimeric proteins
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
ES2678204T3 (es) * 2010-07-30 2018-08-09 Medimmune, Llc Método para purificar inmunoconjugados
DK2771364T3 (da) * 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
WO2013136186A2 (en) 2012-03-13 2013-09-19 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
WO2014078729A1 (en) * 2012-11-15 2014-05-22 Genentech, Inc. IONIC STRENGTH-MEDIATED pH GRADIENT ION EXCHANGE CHROMATOGRAPHY
CN108472360B (zh) 2015-04-10 2023-01-17 阿迪马布有限责任公司 从亲代同源二聚抗体种类中纯化异源二聚多特异性抗体的方法

Also Published As

Publication number Publication date
AU2016245887A1 (en) 2017-11-02
US10787500B2 (en) 2020-09-29
JP2021119207A (ja) 2021-08-12
JP7111767B2 (ja) 2022-08-02
AU2016245887B2 (en) 2021-09-23
US20210047387A1 (en) 2021-02-18
US20180079797A1 (en) 2018-03-22
CN108472360B (zh) 2023-01-17
CA2982131A1 (en) 2016-10-13
JP2018512431A (ja) 2018-05-17
CN108472360A (zh) 2018-08-31
HK1246684A1 (en) 2018-09-14
WO2016164708A1 (en) 2016-10-13
AU2021225195A1 (en) 2021-09-30
JP2020114881A (ja) 2020-07-30
EP3280444B1 (en) 2024-05-08
EP3280444A1 (en) 2018-02-14
EP3280444A4 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
JP7111767B2 (ja) 親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
JP7403505B2 (ja) Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
KR102916929B1 (ko) 카파 및 람다 경사슬을 포함하는 항원-결합 폴리펩티드 구조체 및 이의 용도
JP2018035193A (ja) 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
CA2982131C (en) Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CN117999285A (zh) 包含基于mhc蛋白的异源二聚体的双特异性抗体
AU2018292438B2 (en) Stabilized chimeric fabs
US20260092928A1 (en) Methods of analyzing heterodimeric ¿proteins
WO2024221187A1 (en) Heteromultimer polypeptides
CA3064966C (en) Stabilized chimeric fabs
RU2824193C2 (ru) Антигенсвязывающие полипептидные конструкции, содержащие легкие цепи каппа и лямбда, и их применения
HK40120194A (en) Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190325

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210811

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210811

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210818

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211012

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211014

R150 Certificate of patent or registration of utility model

Ref document number: 6962819

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250